Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cells (UC-MSCs) are a cell therapy product developed by Shandong Province Qilu Stem Cells Engineering, currently being evaluated for the treatment of skin graft donor wounds. UC-MSCs are multipotent stem cells harvested from umbilical cord tissue that possess significant immunomodulatory, anti-inflammatory, and tissue-regenerative properties. In the context of wound healing, these cells are thought to facilitate the repair process by modulating the local immune environment, reducing inflammation, and promoting angiogenesis and re-epithelialization at the donor site. The project is part of the company's clinical research portfolio conducted in collaboration with hospitals in China and is currently in the registered clinical research and filing stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Shandong Province Qilu Stem Cells Engineering).